Published Jul 30, 2026, 8:02 AM ET · Updated 3 months ago · 1 source

A16z-Backed Biotech Braveheart Seeks $318.8 Million in US IPO

bloomberg

Original Report

Braveheart Bio Inc., a clinical-stage biopharmaceutical company backed by a16z, is seeking to raise as much as $318.8 million in an initial public offering, adding to a growing pipeline of listings in the sector.